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Background:  Approximately 30% patients with HF have CSA/CSR. Recent studies showed the benefit of CPAP use, but its response is 
variable in suppressing CSA/CSR. More recent, ASV has emerged for the treatment of this disorder in HF. We aimed to do a meta-analysis 
of ASV in decreasing HF events (cardiac death, worsening EF and HF admission) in patients with severe advanced HF and CSA/CSR.
methods:  PubMed, EMBASE, Cochrane Central data were searched with the following terms: “Sleep Apnea Syndromes” AND “Cheyne-
Stokes Respiration” AND “Heart Failure” OR “Congestive heart failure” AND Adaptive servo ventilation OR ASV. We included studies that 
reported patients with HF and CSA/CSR syndrome comparing the use of ASV versus a control group (either medical therapy, supplemental 
oxygen, CPAP or BiPAP). Random-effect model risk ratio was computed. Heterogeneity was assessed with I2 statistics.
results:  15 studies and 629 patients were included. EF was similar between groups (35 ± 2 vs. 37.7 ± 8 for ASV and control respectively, 
p > 0.05) and the diagnosis of CSA made by polysomnography defined by apnea/hypopnea index (AHI) > 15 episodes/hour did not differ 
statistically (37.5 ± 11 vs. 40.4 ± 10 for ASV and control, p > 0.05). HF events (OR 0.30; CI 0.20-0.44; p<0.00001; figure 1) were less 
prevalent in patients who used ASV.
conclusion:  In patients with severe advanced heart failure and CSA/CSR the use of ASV is associated with a decrease in HF events 
suggesting its use as a first line treatment for CSA/CSR in HF patients.
 
